LABT Lakewood-Amedex Biotherapeutics
$0.29▲ +1.13%
Healthcare
Other
After hours
$0.27▼ -4.12%
Oct 27, 5:51 PM ET
Volume 1.34M
Avg Volume (10D) 4.45M
Key Metrics & Fundamentals
Market Cap
$678,204
P/E Ratio
–
Div Yield
0.00%
52W Range
0.24 - 98.20
% vs 50 MA
-81.02%
% vs 200 MA
–%
RSI-14
18.0
MACD Histogram
+0.0100
Beta (1Y vs SPY)
-0.62
Free Cash Flow
-$2.10M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.73M
COGS
–
Operating Exp
$3.79M
Operating Income
-$3.79M
EBIT
-$3.79M
Pretax Income
-$3.77M
Net Income
-$3.77M
EPS (Diluted)
-2.75
Price & Volume History
Loading chart…
Recent News
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
PR Newswire · Oct 21, 2026 8:02 AM ET
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
PR Newswire · Oct 7, 2026 8:02 AM ET
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
PR Newswire · Oct 1, 2026 8:02 AM ET
Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
InvestorsHub · Sep 28, 2026 10:57 AM ET
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
Zacks Small Cap Research · Sep 28, 2026 8:16 AM ET
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
PR Newswire · Sep 28, 2026 8:02 AM ET
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Benzinga · Sep 24, 2026 10:50 AM ET
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
PR Newswire · Sep 24, 2026 8:02 AM ET
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
PR Newswire · Sep 21, 2026 8:02 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LABT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.